Femoston1 mg+5 mg

Femoston is a combined hormone replacement therapy (HRT) product used in postmenopausal women who have an intact uterus. Its indications are classified below by strength of evidence.

Established / Approved Uses

• Estrogen deficiency symptoms of menopause: Femoston is indicated for the relief of moderate-to-severe vasomotor symptoms (hot flushes, night sweats) and urogenital atrophy symptoms (vaginal dryness, dyspareunia) associated with natural or surgical menopause.
• Prevention of postmenopausal osteoporosis: Femoston is indicated for the prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or have contraindications to, other medicines approved for osteoporosis prevention.

Why the Combination

The dydrogesterone component is added specifically to oppose the endometrial-stimulating effect of estradiol in women who still have a uterus, reducing the risk of endometrial hyperplasia and cancer that can occur with unopposed estrogen therapy. Femoston is not intended for women who have had a hysterectomy, unless there is a specific reason (such as endometriosis) to add a progestogen.

Note: Experience treating women older than 65 years is limited, and Femoston is not indicated for prevention of cardiovascular disease or dementia.

Estradiol + Dydrogesterone tablets contain two active ingredients:

• Estradiol (as estradiol hemihydrate) — a synthetic form of the natural human estrogen, available in strengths such as 1 mg or 2 mg per tablet depending on the formulation.
• Dydrogesterone — a retro-progesterone (progestogen) that is pharmacologically close to natural progesterone, available in strengths such as 5 mg or 10 mg per tablet depending on the formulation.

Formulations are available as continuous-combined (both components taken together every day) or sequential (estradiol alone for part of the cycle, followed by combined estradiol and dydrogesterone tablets) packs, depending on the brand and regimen prescribed.

Femoston is an oral hormone replacement therapy that combines an estrogen (estradiol) with a progestogen (dydrogesterone). It is used to replace the estrogen that the ovaries stop producing after menopause, relieving symptoms caused by the resulting hormone deficiency, while the progestogen component protects the lining of the uterus (endometrium) from the stimulatory effects of estrogen given alone.

Femoston is available as film-coated tablets in blister packs, typically taken once daily, and is used under medical supervision as part of an individualized menopause management plan.

Femoston belongs to the therapeutic class of hormone replacement therapy (HRT) agents, specifically a fixed-dose combination of a natural/synthetic estrogen and a progestogen used in postmenopausal hormone therapy.

Estradiol Component

Estradiol is chemically and biologically identical to endogenous human 17β-estradiol. It replaces the loss of estrogen production in menopausal women and relieves menopausal symptoms. Estradiol also acts on bone to reduce bone resorption and prevent postmenopausal bone loss.

Dydrogesterone Component

Dydrogesterone is an orally active progestogen with actions similar to natural progesterone. It transforms a proliferative endometrium (built up under estrogen stimulation) into a secretory endometrium, which counteracts the increased risk of endometrial hyperplasia and cancer associated with estrogen-only therapy. Unlike many synthetic progestogens, dydrogesterone has minimal androgenic, estrogenic, or corticoid activity at therapeutic doses.

Together, the two components of Estradiol + Dydrogesterone restore hormonal balance similar to the natural menstrual cycle (in sequential regimens) or provide steady combined hormone levels (in continuous-combined regimens), relieving vasomotor and urogenital symptoms while protecting the endometrium.

Femoston tablets are for oral use only. Swallow the tablet whole with water at approximately the same time each day. Follow the arrows on the calendar blister pack to ensure tablets are taken in the correct order, since sequential packs contain estradiol-only and combined tablets in a specific sequence.

The following interactions with Femoston are clinically significant and well documented:

• Hepatic enzyme inducers (e.g., carbamazepine, phenytoin, phenobarbital, rifampicin, rifabutin, and St. John's Wort): may increase the metabolism of estradiol and dydrogesterone, reducing their effectiveness and potentially causing breakthrough bleeding or contraceptive/therapeutic failure.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir): may increase plasma concentrations of estradiol and dydrogesterone, increasing the risk of hormone-related side effects.
• Grapefruit juice: may increase plasma concentrations of estradiol, potentially increasing the risk of side effects.
• Herbal preparations containing St. John's Wort (Hypericum perforatum): can induce estrogen and progestogen metabolism, reducing efficacy of Femoston and causing breakthrough bleeding.

Patients should inform their physician of all prescription, over-the-counter, and herbal products they are taking before starting Femoston.

Side effects with Femoston are generally dose-related and tend to diminish with continued use. Common (may affect more than 1 in 10 people) and other reported effects include:

• Headache, migraine
• Breast tenderness, breast pain, or enlargement
• Abdominal pain, nausea, bloating
• Irregular or breakthrough vaginal bleeding or spotting, especially in the first months of treatment
• Weight changes
• Mood changes, depression
• Leg cramps
• Back pain

Less common but serious risks associated with combined HRT (including Femoston) include an increased risk of venous thromboembolism, stroke, and, with long-term use, breast cancer and gallbladder disease (see Precautions and Warnings and Contraindications). Patients should seek prompt medical attention for symptoms such as leg swelling/pain, sudden chest pain or breathlessness, sudden severe headache, or visual disturbance.

Pregnancy: Femoston is contraindicated during pregnancy. It is intended for use only in postmenopausal women, and there is no indication for its use during pregnancy. If pregnancy occurs or is suspected during treatment, Femoston should be stopped immediately and a physician consulted.

Lactation: Femoston is not indicated for use during breastfeeding. It is not recommended for use in nursing mothers, as hormone components may be excreted in breast milk and may affect milk production and composition. A physician should be consulted for alternative approaches if hormone therapy is being considered while breastfeeding.

Before starting Femoston, a complete personal and family medical history should be taken, including a relevant physical examination, and treatment should be re-evaluated periodically.

• Cardiovascular risk: combined HRT, including Femoston, is associated with a small increased risk of venous thromboembolism and, in some populations, stroke and coronary heart disease, particularly with longer duration of use and in older women; the risk should be weighed against benefits for each patient.
• Breast cancer risk: long-term use of combined estrogen-progestogen HRT is associated with an increased risk of breast cancer; this risk increases with duration of use and reverses within a few years of stopping treatment.
• Gallbladder disease: estrogen therapy is associated with an increased risk of gallbladder disease requiring surgery.
• Endometrial safety: unscheduled/breakthrough bleeding should be investigated to exclude endometrial pathology, especially if it persists or occurs after a time of amenorrhea.
• Other conditions requiring caution: uterine fibroids, endometriosis, history of endometrial hyperplasia, risk factors for estrogen-dependent tumors, hypertension, hepatic or renal disorders (including benign liver tumors), diabetes mellitus, gallstones, migraine or severe headache, systemic lupus erythematosus, epilepsy, asthma, otosclerosis, and hereditary angioedema.
• Femoston does not provide contraception and is not intended for women who could still be fertile without additional contraceptive protection where relevant.

Femoston has low acute toxicity. Overdosage may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness/fatigue, and withdrawal bleeding in women. There is no specific antidote. In case of a suspected overdose, seek immediate medical attention or contact a poison control center; treatment should be symptomatic and supportive, as directed by a physician.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly

Experience with Femoston in women older than 65 years is limited. There is no evidence that older postmenopausal women require a different dose, but the lowest effective dose for the shortest duration is recommended given the age-related increase in cardiovascular and breast cancer risk.

Hepatic Impairment

Femoston is contraindicated in active liver disease or a history of liver disease with abnormal liver function tests that have not normalized. Women with well-compensated chronic liver conditions should be monitored closely if treatment is considered necessary.

Renal Impairment

Specific studies in renal impairment have not been conducted; caution is advised and use should be guided by clinical judgment.

Pediatric Population

Femoston is not indicated for use in children or adolescents; safety and efficacy have not been established in this population.

Femoston should be used for the shortest duration necessary to control symptoms, at the lowest effective dose. Treatment should be reviewed by the physician at least once a year, weighing the ongoing benefits (symptom control, osteoporosis prevention) against the risks (including venous thromboembolism and breast cancer) that increase with duration of use.

Hormone replacement therapy (estrogen + progestogen combination)

Estradiol + Dydrogesterone works by supplying exogenous estradiol to replace the estrogen that declines after menopause, relieving vasomotor and urogenital symptoms and helping to maintain bone mineral density. The added dydrogesterone converts the estrogen-stimulated (proliferative) endometrium into a secretory state and induces regular shedding (in sequential regimens) or maintains endometrial quiescence (in continuous-combined regimens), thereby protecting against the endometrial hyperplasia and cancer risk that unopposed estrogen would otherwise cause in women with an intact uterus.

X

Femoston is not indicated for use in the pediatric population. Safety and efficacy in children and adolescents have not been established, and there is no recognized clinical use for this combination outside of postmenopausal hormone replacement in adult women.